SCHEMBL2875121

SCHEMBL2875121

CCOC(=O)c1[c]nccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.47
TSHR P16473 2/20 0.47
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
BRD4 O60885 1/20 0.43
PDE4A P27815 1/20 0.41
ALDH1A1 P00352 3/20 0.41
HSD17B10 Q99714 1/20 0.41
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
PDE4D Q08499 1/20 0.40
NPSR1 Q6W5P4 2/20 0.40
HTT P42858 1/20 0.40
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
KDM4E B2RXH2 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12984487 0.87 ALDH1A1 (0.50) TSHRALDH1A1ESR1MAPTLMNA
SCHEMBL10590983 0.81 L3MBTL1 (0.37) CYP1A2TSHRBRD4ALDH1A1HTT
SCHEMBL1032794 0.80 ALDH1A1 (0.46) TSHRCA12CA1CA2CA7
SCHEMBL12983825 0.77 SMN1; SMN2 (0.36) MAPTNPC1GAAHPGDRAB9A
SCHEMBL4910908 0.76 CYP1A2 (0.43) CYP1A2TSHRCA12CA1CA2
SCHEMBL131249 0.76 CA12 (0.57) CYP1A2TSHRCA12CA1CA2
SCHEMBL3761435 0.75 TSHR (0.56) CYP1A2TSHRALDH1A1HSD17B10HTT
SCHEMBL11741705 0.74 CYP1A2 (0.44) CYP1A2TSHRCA12CA1CA2
SCHEMBL1854440 0.73 LMNA (0.43) ALDH1A1HSD17B10HTTMAPTLMNA
SCHEMBL3639242 0.73 ADRA1D (0.35) ALDH1A1HSD17B10HTTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740478-B1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2023-11-01 EP disclosed
CN-111601799-B Fused imidazole derivatives as Il-17 modulators UCB生物制药有限责任公司 2023-06-09 CN disclosed
US-11472794-B2 Fused imidazole derivatives as IL-17 modulators UCB Biopharma SRL (BE) 2022-10-18 US disclosed
US-20220227764-A1 Imidazopyridine Derivatives as IL-17 Modulators UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) 2022-07-21 US disclosed
EP-3990451-A1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2022-05-04 EP disclosed
CN-114026084-A Fused imidazole derivatives as IL-17 modulators UCB生物制药有限责任公司 2022-02-08 CN disclosed
CN-113906025-A Imidazopyridine derivatives as IL-17 modulators UCB生物制药有限责任公司 2022-01-07 CN disclosed
US-20210053952-A1 Fused Imidazole Derivatives as IL-17 Modulators UCB Biopharma SRL (BE) 2021-02-25 US disclosed
WO-2020260425-A1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2020-12-30 WO disclosed
WO-2020260426-A1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2020-12-30 WO disclosed
WO-1996022982-A1 SULPHONYL AMINO(THIO)CARBONYL-1,2,4-TRIAZOLIN(THI)ONE DERIVATIVES, THE PRODUCTION THEREOF AND THE USE THEREOF AS HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 1996-08-01 WO disclosed
EP-0270683-B1 ARYLOXYUREAS, PROCESS FOR THEIR PREPARATION, AND THEIR USE MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1992-09-09 EP disclosed
US-5112385-A Useful in rice paddies KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 1992-05-12 US disclosed
WO-1991006541-A1 SULPHONATED HETEROCYCLIC CARBOXAMIDES AS HERBICIDES, GROWTH REGULATORS OR FUNGICIDES HOECHST AKTIENGESELLSCHAFT (DE) 1991-05-16 WO disclosed
US-4968341-A PRE-AND POSTEMERGENCE HERBICIDES KUMIAI CHEMICAL INDUSTRY CO. (JP) 1990-11-06 US disclosed
EP-0353640-A2 Heterocyclic N-acylsulphonamides, process for their preparation, agents containing them and their use as herbicides and plant growth regulators Hoechst Schering AgrEvo GmbH (DE) 1990-02-07 EP disclosed
EP-0270683-A1 ARYLOXYUREAS, PROCESS FOR THEIR PREPARATION, AND THEIR USE MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1988-06-15 EP disclosed
US-4434174-A Treating cardiovascular diseases with N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines BERLEX LABORATORIES, INC. (US) 1984-02-28 US disclosed
US-4363808-A N-(3-Phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines BERLEX LABORATORIES, INC. (US) 1982-12-14 US disclosed
EP-0034116-A2 N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines BERLEX LABORATORIES, INC. (US) 1981-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11472794-B2 Fused imidazole derivatives as IL-17 modulators IL17A, IL2, IL23R CYP1A2 1018/4885TSHR 2077/4885CA12 4682/4885
US-20220227764-A1 Imidazopyridine Derivatives as IL-17 Modulators IL17A, IL2, IL23R CYP1A2 447/4885TSHR 1771/4885CA12 4698/4885
US-20210053952-A1 Fused Imidazole Derivatives as IL-17 Modulators IL17A, IL2, IL23R CYP1A2 1018/4885TSHR 2077/4885CA12 4682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.